What's the deal? Faro has raised a $37 million Series B round to develop AI tools aimed at speeding up clinical trials. The startup wants to address the long, costly slog of testing drugs in patients — a stage that comes after a molecule is designed. Why now? Countless startups are already using AI to design molecules faster and cheaper. Far fewer are targeting what comes next: the clinical trial process, where Faro sees an opening. What's the endgame? Faro is betting AI can compress trial timel...